DIA Biosimilars 2013

Duke Clinical Research Institute

Theorem Clinical Research names Joseph Sgherza head of infectious diseases

Tuesday, October 1, 2013 09:44 AM

Global CRO Theorem Clinical Research has named Joseph Sgherza vice president of biopharmaceutical development for its infectious disease franchise. Sgherza has 24 years in the pharmaceutical, biotech and CRO industries.

More... »

Cenduit: Now with Patient Reminders

Benitec selects Duke Clinical Research Unit as a site for HCV phase I/II trial

Monday, March 25, 2013 11:03 AM

RNAi-based therapeutics company Benitec Biopharma has selected the Duke Clinical Research Unit, the early phase unit of the Duke Clinical Research Institute (DCRI) of Durham, N.C., as a site for its upcoming phase I/II first-in-man trial for TT-034 in hepatitis C (HCV). TT-034 is being developed as a potential "one-shot-cure" for HCV.

More... »

CRF Health – eCOA Forum

UL acquires EduNeering

Tuesday, April 10, 2012 06:30 AM

Global safety science company UL has acquired EduNeering, a provider of compliance and training solutions for the life and health sciences sector, from educational and career service Kaplan.

More... »

CenterWatch Drugs in Clinical Trials Database Library. Drug intelligence right at your fingertips.
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs